ARTICLE | Company News
MorphoSys and ImmunoGen in cancer deal
October 2, 2000 7:00 AM UTC
MorphoSys (NMarkt:MOR) will use its HuCAL-Fab technology to discover and optimize human antibodies against an IMGN cell surface target, associated with a number of cancers. MOR will receive a technolo...